Federal plan targets antidepressant prescriptions amid expert warnings over medical misinformation

Health Secretary Robert F. Kennedy Jr. has announced a series of federal initiatives aimed at reducing the prescribing of antidepressants, specifically Selective Serotonin Reuptake Inhibitors (SSRIs), at a Make America Healthy Again Institute event. The announcement includes mandatory training for clinicians, a Dear Colleague Letter encouraging providers to prioritise non-medical alternatives, and new guidance from the Centers for Medicare & Medicaid Services (CMS) introducing a specific billing code to facilitate deprescribing.

The plan relies heavily on assertions that have been widely debunked by medical experts, including claims that SSRIs are as addictive as heroin and that they induce violence. During the event, Kennedy repeated the comparison between antidepressants and heroin, a statement he made during his January 2025 confirmation hearing and which was subsequently contradicted by addiction specialists who noted the two substances exist in different universes regarding addiction risk.

Critics argue that the new federal steps oversimplify a complex national mental health crisis. The American Psychiatric Association stated that while they welcome attention to the issue, they strongly object to framing the situation as one of overmedicalisation or overprescribing. The association highlighted that the current crisis is driven by systemic access issues and uneven care distribution, noting that many patients cannot access timely, comprehensive treatment.

Medical groups have also pointed to research suggesting that safety warnings regarding antidepressants can inadvertently reduce access to care. A 2024 study in Health Affairs found that similar FDA warnings from 2003 led to reduced physician visits and antidepressant use, correlating with increases in psychotropic drug poisonings and suicide deaths. Experts warn that Kennedy's messaging carries similar dangers, potentially driving patients away from lifesaving medical care.

The proposed measures include a Dear Colleague Letter that promotes non-pharmacological treatments such as exercise, nutrition, and therapy, while emphasising the risks and benefits of medication. Additionally, the CMS guidance includes a new billing code designed to make it financially easier for providers to step patients off these medications. However, the specific timeline for the rollout of clinician training and the extent to which private practices will adopt the Dear Colleague Letter remain uncertain.

Despite the federal push, psychiatrists maintain that prescribing and deprescribing are part of individualised, evidence-based treatment planning. The American Psychiatric Association emphasised that the solution lies not in stigmatising psychiatric medication or imposing broad assumptions on clinical care, but in ensuring patients have access to the full range of evidence-based treatments guided by the best available science.